Literature DB >> 1444923

Toxicity of intravitreous ceftazidime in primate retina.

P A Campochiaro1, W R Green.   

Abstract

Squirrel monkeys were anesthetized and given intravitreous injections of 0.1 mL of balanced salt solution containing 0 mg (two eyes), 1 mg (three eyes), 2.25 mg (three eyes), or 10 mg (three eyes) of ceftazidime, a third-generation cephalosporin that provides excellent coverage for gram-negative infections. Ophthalmoscopic examinations were performed 48 hours after the injections and results were completely normal in all eyes except for those that were injected with 10 mg of ceftazidime, all three of which showed the appearance of cystic change in the macula. The monkeys were killed and the eyes were removed and examined by light and electron microscopy. All eyes were normal by light microscopy except for those injected with 10 mg of ceftazidime, which showed disruption of photoreceptors (primarily outer segments) in the foveas with cystic changes in all three and macular holes in two of three. Electron microscopy showed mild swelling of mitochondria and perinuclear halos around photoreceptor nuclei in both control eyes and in eyes injected with 1 and 2.25 mg. An eye injected with 10 mg showed severe damage to central photoreceptor outer segments consisting of disruption of plasma membranes and accumulation of intracytoplasmic granular material. Inner segments showed mild changes and there was loss of apical microvilli of the retinal pigmented epithelium. The inner retina was normal. These data suggest that high doses of intravitreous ceftazidime show toxicity primarily to photoreceptor cells, but a dose of 2.25 mg is safe as studied in this model and can be used instead of intravitreous aminoglycosides that have a narrow therapeutic window.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1444923     DOI: 10.1001/archopht.1992.01080230125035

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  9 in total

1.  Macular infarction after intravitreal amikacin: mounting evidence against amikacin.

Authors:  G Galloway; A Ramsay; K Jordan; A Vivian
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

Review 2.  Current approach to postoperative endophthalmitis.

Authors:  G Sunaric-Mégevand; C J Pournaras
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

Review 3.  Bacillus cereus endophthalmitis.

Authors:  D B David; G R Kirkby; B A Noble
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

Review 4.  Infectious endophthalmitis after cataract surgery.

Authors:  D S Hughes; R J Hill
Journal:  Br J Ophthalmol       Date:  1994-03       Impact factor: 4.638

Review 5.  Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.

Authors:  G A Stern
Journal:  Trans Am Ophthalmol Soc       Date:  1993

6.  An in vitro study on the compatibility and precipitation of a combination of ciprofloxacin and vancomycin in human vitreous.

Authors:  M Hui; A K H Kwok; C P Pang; S W Cheung; R C Y Chan; D S C Lam; A F B Cheng
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

7.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993

Review 8.  A Review of Antimicrobial Therapy for Infectious Uveitis of the Posterior Segment.

Authors:  Ahmed B Sallam; Kyle A Kirkland; Richard Barry; Mohamed Kamel Soliman; Tayyeba K Ali; Sue Lightman
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2018

9.  Pharmacokinetics of Intravitreal Vancomycin and Ceftazidime in Silicone Oil-Filled Macaque Eyes.

Authors:  Taku Imamura; Masashi Kakinoki; Daiki Hira; Tomoya Kitagawa; Satoshi Ueshima; Mikio Kakumoto; Tomohiro Terada; Ikuo Kawamoto; Mitsuru Murase; Masahito Ohji
Journal:  Transl Vis Sci Technol       Date:  2021-03-01       Impact factor: 3.283

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.